Physician profile
James P Powers
NPI 1578553574
$817.26
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $108 · 2021: $105 · 2022: $34.59 · 2023: $62.33 · 2024: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.60 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $173.82 | 2024 | |
| Orthofix Medical, INC. | $135.16 | 2019 | |
| Allergan, INC. | $76.45 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $63.88 | 2020-2021 | |
| Genentech USA, INC. | $63.74 | 2019-2024 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $54.80 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.19 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $35.71 | 2023 | Acthar |
| Bausch & Lomb Americas INC. | $35.68 | 2024 | Miebo |
| Novartis Pharmaceuticals Corporation | $30.25 | 2020 | |
| Astellas Pharma US INC | $27.25 | 2024 | Izervay |
| Coherus Oncology, INC. | $26.62 | 2023 | |
| Oyster Point Pharma, INC. | $18.96 | 2022 | |
| Abbvie INC. | $15.63 | 2022 | |
| Sight Sciences, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.